Hengrui’s Docetaxel Use Ruled Not Infringing On Sanofi-Aventis’ Patent
This article was originally published in PharmAsia News
Hengrui China's Patent Re-examination Board of the State Intellectual Property Office (SIPO) has ruled that the patent right of Aventis Pharma S.A. and Sanofi-Aventis for Docetaxel is invalid. If dissatisfied with the verdict, the plaintiffs can appeal to the Beijing Number One Intermediate People's Court within three months. Last September, Aventis Pharma and Sanofi-Aventis sued Jiangsu Hengrui in Beijing Municipal Higher People's Court for Docetaxel patent infringement, asking for patent fees of 45 million yuan ($6.4 million), financial loss compensation of 55 million yuan ($7.87 million), miscellaneous expenses of 200,000 yuan ($28,000) and full cost of the litigation. (Click here for more - Chinese language)
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.